Analysts Issue Forecasts for Immunome FY2027 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Analysts at Lifesci Capital issued their FY2027 earnings estimates for Immunome in a research note issued to investors on Tuesday, May 12th. Lifesci Capital analyst C. Zhu forecasts that the company will earn ($1.94) per share for the year. The consensus estimate for Immunome’s current full-year earnings is ($2.50) per share.

Several other research firms have also recently weighed in on IMNM. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Truist Financial upgraded shares of Immunome to a “strong-buy” rating in a report on Monday, May 4th. Stephens reduced their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Immunome in a report on Wednesday. Finally, Craig Hallum increased their target price on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.45.

Immunome Stock Down 2.2%

Immunome stock opened at $22.20 on Thursday. The stock has a market capitalization of $2.51 billion, a PE ratio of -9.33 and a beta of 2.11. Immunome has a twelve month low of $7.42 and a twelve month high of $27.65. The company has a 50 day moving average of $21.98 and a 200-day moving average of $21.14.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12.

Insider Buying and Selling at Immunome

In other Immunome news, insider Jack Higgins sold 9,438 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares in the company, valued at $476,080. This trade represents a 30.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 28,200 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $20.65, for a total transaction of $582,330.00. Following the completion of the sale, the director owned 341,147 shares of the company’s stock, valued at approximately $7,044,685.55. This represents a 7.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 139,438 shares of company stock worth $2,964,664 over the last quarter. 7.21% of the stock is currently owned by insiders.

Institutional Trading of Immunome

A number of large investors have recently added to or reduced their stakes in IMNM. Sei Investments Co. raised its position in shares of Immunome by 90.4% in the first quarter. Sei Investments Co. now owns 52,770 shares of the company’s stock valued at $1,154,000 after purchasing an additional 25,051 shares during the period. Walleye Capital LLC bought a new position in shares of Immunome in the first quarter valued at about $2,432,000. KBC Group NV bought a new position in shares of Immunome in the first quarter valued at about $60,000. Assetmark Inc. raised its position in shares of Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after purchasing an additional 1,442 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Immunome by 4.8% in the first quarter. Bank of New York Mellon Corp now owns 276,066 shares of the company’s stock valued at $6,038,000 after purchasing an additional 12,692 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.